IRLAB Therapeutics (IRLAB-A.ST) Stock Analysis & AI Equity Report
IRLAB Therapeutics (IRLAB-A.ST) overview
IRLAB Therapeutics (IRLAB-A.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, IRLAB Therapeutics reported revenue of SEK 94.6m and operating profit of SEK -75.1m; the year-end share price was 10.75 SEK and market capitalisation was SEK 558m. IRLAB Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get IRLAB Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About IRLAB Therapeutics
IRLAB Therapeutics AB is a Swedish biotechnology company that discovers and develops treatments for Parkinson’s disease and other central nervous system disorders. Its pipeline includes clinical and preclinical drug candidates, and its value driver is the proprietary Integrative Screening Process research platform, which is used to identify and advance new drug candidates.
Generate the IRLAB Therapeutics report
IRLAB Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for IRLAB Therapeutics and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.